predictor
fatal
adenoviru
adv
pneumonia
among
immunocompet
adult
unclear
laboratoryconfirm
hospit
adv
pneumonia
adult
prospect
enrol
beij
chaoyang
hospit
march
june
clinic
data
serial
whole
blood
respiratori
tract
secret
patient
collect
quantit
realtim
polymeras
chain
reaction
perform
quantifi
viral
load
total
adv
pneumonia
case
consecut
enrol
four
fatal
ten
case
caus
three
one
differ
age
gender
underli
diseas
patient
fatal
case
surviv
case
admiss
day
ill
onset
patient
fatal
case
present
higher
initi
viral
load
respiratori
tract
secret
vs
log
copiesml
p
patient
fatal
case
present
viremia
day
vs
p
higher
initi
viral
load
respiratori
tract
sustain
viremia
week
may
predictor
fatal
clinic
outcom
fig
kinet
adv
load
sequenti
sputum
whole
blood
ckmb
ctni
level
male
surviv
patient
myocard
yaxi
viral
load
level
present
log
dna
copi
number
per
ml
sampl
myocardi
enzym
level
express
log
ckmb
ngml
log
ctni
ngml
ckmb
creatin
kinasemb
ctni
cardiac
troponin
sever
adenoviru
adv
infect
caus
signific
acut
respiratori
distress
syndrom
rais
concern
immunocompet
adult
sever
case
previous
report
associ
new
strain
formerli
known
major
adv
pneumonia
pathogen
immunocompet
adolesc
adult
china
sinc
previou
studi
identifi
fatal
infect
case
patient
present
system
infect
highlevel
viremia
howev
even
though
well
caus
sever
case
strain
necessarili
associ
bad
outcom
pathogenesi
fatal
still
unknown
alreadi
ascertain
adv
detect
whole
blood
specimen
sever
case
still
lack
knowledg
viral
shed
histori
relationship
viral
clearanc
respiratori
tract
viremia
durat
clinic
outcom
studi
focu
dynam
virolog
chang
whole
blood
respiratori
tract
secret
see
lethal
case
experienc
high
viral
load
longer
durat
viral
shed
compar
nonleth
case
hypothes
sustain
viru
shed
blood
andor
respiratori
tract
appear
sever
immunocompet
adult
case
may
risk
factor
fatal
outcom
studi
review
approv
institut
review
board
beij
chaoyang
hospit
project
approv
number
written
inform
consent
provid
adult
parent
patient
age
less
year
adult
communityacquir
pneumonia
cap
admit
beij
chaoyang
hospit
march
june
prospect
includ
patient
hiv
infect
neutropenia
receiv
immunosuppress
chemotherapi
steroid
equival
prednison
mgd
day
pregnant
breast
feed
women
known
suspect
activ
tuberculosi
exclud
method
etiolog
evalu
follow
standard
adult
suspect
cap
short
sputum
respiratori
tract
aspir
blood
urin
collect
admiss
submit
infecti
diseas
clinic
microbiolog
laboratori
microbiolog
method
base
follow
test
sputum
specimen
gram
stain
cultur
consid
valid
microscopi
show
neutrophil
epitheli
cell
per
low
field
microscopi
urin
specimen
rapid
detect
pneumonia
legionella
pneumophila
antigen
blood
cultur
sputum
tracheal
aspir
viru
realtim
polymeras
chain
reaction
pcr
detect
includ
rhinoviru
influenza
b
respiratori
syncyti
viru
b
adenoviru
parainfluenza
coronaviru
metapneumoviru
sputum
mycoplasma
pneumonia
pcr
detect
subject
posit
adenoviru
result
neg
etiolog
studi
period
enrol
result
pcr
test
respiratori
virus
report
clinician
within
hour
sputum
collect
posit
adv
pcr
test
serial
whole
blood
respiratori
tract
sampl
collect
death
discharg
studi
tri
collect
type
respiratori
tract
sampl
patient
carri
serial
viral
load
test
lower
bia
differ
type
sampl
patient
mechan
ventil
collect
serial
tracheal
aspir
patient
without
mechan
ventil
collect
sputum
sampl
also
collect
data
regard
age
gender
comorbid
clinic
symptom
vital
sign
antimicrobi
treatment
chest
radiograph
find
laboratori
result
record
complic
includ
follow
use
mechan
ventil
extracorpor
membran
oxygen
ecmo
second
bacteri
fungal
infect
patient
also
follow
discharg
death
respiratori
tract
sampl
includ
sputum
tracheal
aspir
process
equal
volum
trypsin
digest
viral
dna
extract
millilit
ml
digest
respiratori
sampl
ml
whole
blood
sampl
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
usa
first
amplifi
entir
hexon
gene
sampl
pcr
primer
sequenc
list
tabl
adv
type
determin
use
blast
http
blastncbinlmnihgovblastcgi
regard
quantif
adv
sampl
use
commerci
fqpcr
kit
daan
gene
cat
guangzhou
china
target
dna
polymeras
gene
genebank
twotail
independ
sampl
ttest
mannwhitney
utest
condit
nonnorm
distribut
use
compar
continu
variabl
two
group
categor
data
univari
analysi
perform
use
chisquar
test
fisher
exact
test
signific
fix
p
valu
data
analysi
perform
use
spss
spss
inc
chicago
il
march
june
total
admit
case
confirm
adenoviru
pathogen
pneumonia
four
patient
die
icu
mean
age
year
old
male
predomin
number
femal
sex
ratio
approxim
two
patient
comorbid
one
tubercul
pleuriti
month
one
congenit
heart
diseas
differ
age
gender
underli
diseas
fatal
case
surviv
case
three
type
adv
found
studi
n
n
n
ratio
fatal
group
similar
surviv
group
vs
p
tabl
clinic
featur
comparison
surviv
fatal
case
clinic
symptom
sign
note
surviv
case
fatal
case
differ
except
pneumonia
sever
index
psi
score
dyspnea
fatal
case
higher
psi
score
dyspnea
incid
compar
psi
score
dyspnea
incid
surviv
case
p
respect
tabl
fatal
case
describ
bilater
involv
chest
radiographi
note
pleural
effus
tabl
surviv
case
note
bilater
involv
describ
pleural
effus
signific
differ
two
group
bilater
involv
pleural
effus
adv
load
track
respiratori
tract
sampl
whole
blood
mean
time
diseas
onset
initi
pcr
test
respiratori
tract
sampl
whole
blood
day
signific
differ
fatal
group
surviv
group
measur
adenovir
load
respiratori
tract
sampl
whole
blood
express
log
dna
copi
per
ml
sampl
initi
viral
load
respiratori
tract
sampl
day
diseas
onset
result
show
compar
surviv
case
fatal
case
higher
initi
viral
load
vs
p
fig
howev
initi
viral
load
whole
blood
signific
differ
two
group
vs
p
fig
also
investig
viral
shed
durat
evalu
posit
ratio
day
day
ill
onset
respiratori
tract
sampl
signific
differ
viral
posit
ratio
two
group
either
day
vs
day
onset
diseas
vs
p
fig
viremia
common
admiss
day
onset
ill
note
fatal
case
surviv
case
p
day
onset
ill
howev
persist
fatal
case
surviv
case
p
fig
surviv
sever
patient
found
clinic
manifest
recov
gradual
downward
trend
viral
load
respiratori
tract
whole
blood
sampl
shown
fig
yearold
male
acut
respiratori
distress
syndrom
ard
high
initi
viral
load
copiesml
tracheal
aspir
condit
improv
sputum
viral
load
go
day
ecmo
withdrawn
day
viral
load
blood
go
neg
day
clinic
condit
significantli
improv
patient
need
oxygen
therapi
chest
xray
also
remark
resolv
shown
fig
respiratori
tract
viral
load
male
ard
also
high
initi
viral
load
copiesml
tracheal
aspir
viral
load
tracheal
aspir
gradual
decreas
first
day
lung
infiltr
absorb
partial
howev
viral
load
trend
patient
die
also
maintain
viral
load
whole
blood
death
antibiot
given
patient
empir
confirm
diagnosi
current
formal
approv
antivir
therapi
treatment
sever
lifethreaten
adenoviru
infect
china
acyclovir
ganciclovir
ribavirin
commonli
chosen
physician
treat
adenovir
infect
studi
fatal
patient
administ
antivir
drugson
treat
ganciclovir
two
acyclovir
one
ribavirin
surviv
patient
treat
antivir
drugsthre
ganciclovir
one
acyclovir
one
ribavirin
fatal
patient
complic
ard
admit
icu
need
mechan
ventil
three
receiv
ecmo
maintain
oxygen
surviv
patient
one
admit
icu
due
ard
mechan
ventil
ecmo
one
patient
respiratori
failur
treat
noninvas
ventil
one
patient
treat
myocard
myocard
patient
present
peak
level
creatin
kinas
isoenzym
ckmb
cardiac
troponin
ctni
day
diseas
onset
eight
day
later
viral
load
go
neg
ckmb
ctni
went
normal
level
parallel
fig
four
fatal
patient
time
death
day
diseas
onset
respect
signific
differ
length
stay
inhospit
two
group
day
vs
day
p
tabl
three
patient
complic
bacteri
fungal
infect
among
fatal
case
first
patient
present
consecut
aspergillu
fumigatu
tracheal
aspir
cultur
second
patient
caviti
present
chest
ct
third
patient
acinetobact
baumannii
tracheal
aspir
pleural
effus
cultur
two
patient
complic
superinfect
surviv
patient
one
patient
male
present
typic
crescent
sign
halo
sign
chest
ct
followup
voriconazol
administ
resolv
condit
fig
anoth
patient
ecmo
present
acinetobact
baumannii
tracheal
aspir
investig
relationship
virolog
factor
clinic
outcom
cohort
hospit
adult
adv
pneumonia
result
suggest
higher
initi
viral
load
copyml
respiratori
tract
sampl
day
diseas
onset
predictor
fatal
clinic
outcom
also
report
viremia
common
sustain
viremia
day
may
associ
mortal
pathogenesi
mortal
adv
pneumonia
still
unknown
virolog
factor
eg
new
strain
new
genet
viral
load
slow
viru
clearanc
system
infect
viremia
like
play
key
role
sever
adv
howev
studi
evalu
viral
shed
histori
among
immunocompet
adult
adv
pneumonia
studi
first
monitor
consecut
viral
load
respiratori
tract
sampl
whole
blood
sampl
previou
clinic
studi
demonstr
day
diseas
onset
peak
stage
ill
present
patient
short
breath
sever
dyspnea
studi
show
viral
load
day
could
also
provid
insight
sever
ill
evid
even
prove
higher
level
viral
load
respiratori
tract
sampl
day
diseas
onset
significantli
associ
fatal
outcom
note
viremia
quit
common
day
diseas
onset
patient
viremia
adenoviru
viremia
found
hematopoiet
stem
cell
transplant
recipi
associ
adv
diseas
compar
previou
report
viremia
clinic
outcom
anoth
novel
find
demonstr
fatal
outcom
could
predict
sustain
viremia
viremia
studi
show
patient
fatal
case
present
viremia
day
diseas
onset
compar
p
patient
surviv
case
one
case
shown
fig
even
though
patient
present
higher
viral
load
copi
ml
tracheal
aspir
may
associ
fatal
outcom
clinic
manifest
recov
gradual
downward
trend
viral
load
respiratori
tract
whole
blood
sampl
compar
case
fig
patient
describ
fig
higher
viral
load
copiesml
tracheal
aspir
also
present
sustain
elev
viral
copi
especi
whole
blood
shike
et
al
also
report
infant
system
infect
adenoviru
highlevel
viremia
show
reduct
viral
load
parallel
clinic
recoveri
therefor
sever
case
dynam
monitor
viral
shed
especi
whole
blood
could
help
predict
clinic
outcom
patient
might
bad
outcom
viral
load
whole
blood
present
signific
downward
trend
around
two
week
diseas
onset
current
formal
approv
antivir
therapi
treatment
sever
lifethreaten
adenoviru
infect
china
cidofovir
consid
medicin
choic
sever
infect
immunocompromis
patient
cidofovir
avail
hospit
china
includ
hospit
acyclovir
ganciclovir
ribavirin
usual
prescrib
china
studi
antivir
drug
administ
fatal
caseson
patient
treat
ganciclovir
two
acyclovir
one
ribavirin
surviv
patient
treat
antivir
drugsthre
ganciclovir
one
acyclovir
one
ribavirin
choic
antivir
medicin
decid
patient
physician
none
three
medicin
confirm
effect
adv
infect
relationship
viral
shed
clinic
outcom
studi
associ
antiadenovir
treatment
effect
studi
two
limit
adv
common
infect
type
studi
result
might
signific
adv
pneumonia
might
generaliz
type
adv
pneumonia
previou
studi
adult
infect
adv
year
older
present
higher
psi
score
compar
adult
infect
serotyp
anoth
limit
descript
work
may
small
number
analyz
patient
especi
group
fatal
case
n
case
need
confirm
find
conclus
data
provid
new
insight
virolog
adv
pneumonia
higher
initi
viral
load
copyml
respiratori
tract
day
diseas
onset
sustain
viremia
week
may
associ
fatal
clinic
outcom
